Your browser is no longer supported. Please, upgrade your browser.
Settings
DVAX Dynavax Technologies Corporation daily Stock Chart
DVAX [NASD]
Dynavax Technologies Corporation
Index- P/E- EPS (ttm)-2.54 Insider Own1.40% Shs Outstand58.34M Perf Week18.05%
Market Cap232.78M Forward P/E- EPS next Y-0.87 Insider Trans-11.07% Shs Float58.34M Perf Month9.02%
Income-159.60M PEG- EPS next Q-0.44 Inst Own82.40% Short Float27.50% Perf Quarter-36.67%
Sales13.80M P/S16.87 EPS this Y-40.90% Inst Trans1.55% Short Ratio9.36 Perf Half Y-64.15%
Book/sh0.68 P/B5.87 EPS next Y56.70% ROA-63.10% Target Price22.75 Perf Year-68.71%
Cash/sh3.14 P/C1.27 EPS next 5Y- ROE-190.00% 52W Range2.60 - 14.35 Perf YTD-56.39%
Dividend- P/FCF- EPS past 5Y7.80% ROI-93.50% 52W High-72.20% Beta0.63
Dividend %- Quick Ratio4.60 Sales past 5Y-6.10% Gross Margin36.90% 52W Low53.76% ATR0.31
Employees249 Current Ratio5.30 Sales Q/Q562.00% Oper. Margin- RSI (14)68.86 Volatility10.99% 9.83%
OptionableYes Debt/Eq4.07 EPS Q/Q1.40% Profit Margin- Rel Volume0.76 Prev Close3.91
ShortableNo LT Debt/Eq4.07 EarningsAug 07 AMC Payout- Avg Volume1.71M Price3.99
Recom1.80 SMA2027.86% SMA5010.99% SMA200-48.24% Volume1,309,633 Change2.05%
Jul-11-19Upgrade Cantor Fitzgerald Neutral → Overweight $20
Feb-27-19Reiterated Cantor Fitzgerald Overweight $32 → $28
May-10-18Upgrade JP Morgan Neutral → Overweight
Mar-08-18Reiterated Cantor Fitzgerald Overweight $25 → $27
Feb-14-18Downgrade JP Morgan Overweight → Neutral
Sep-25-17Reiterated RBC Capital Mkts Outperform $26 → $28
Sep-15-17Initiated Cantor Fitzgerald Overweight $24
Jul-31-17Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $26
Jul-31-17Upgrade JP Morgan Neutral → Overweight
May-09-17Reiterated RBC Capital Mkts Sector Perform $6 → $7
Apr-28-16Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $17
Apr-27-16Downgrade JP Morgan Overweight → Neutral
Nov-30-15Initiated RBC Capital Mkts Outperform $48
Nov-25-13Upgrade MLV & Co Hold → Buy $1.50 → $5
Feb-25-13Downgrade MLV & Co Buy → Hold
Nov-16-12Reiterated MLV & Co Buy $10 → $7.50
Jan-04-12Initiated MLV & Co Buy $8
Nov-09-10Reiterated Wedbush Outperform $6 → $8
Nov-08-10Initiated Jefferies Buy $4
May-13-10Upgrade Wedbush Neutral → Outperform $2.60 → $6
Aug-12-19 04:05PM  Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors GlobeNewswire
Aug-11-19 10:12PM  Edited Transcript of DVAX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 05:16PM  Dynavax Technologies Corp (DVAX) Q2 2019 Earnings Call Transcript Motley Fool
08:00AM  Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock GlobeNewswire
Aug-07-19 06:45PM  Dynavax Technologies (DVAX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:12PM  Dynavax Technologies Announces Proposed Public Offering of Common Stock, Non-Voting Preferred Stock and Warrants to Purchase Common Stock GlobeNewswire
04:01PM  Dynavax Announces Second Quarter 2019 Financial Results GlobeNewswire
Jul-24-19 04:05PM  Dynavax Technologies to Report Second Quarter 2019 Financial Results and Host Conference Call on August 7 GlobeNewswire
Jul-23-19 11:00AM  Are These 2 Beaten-Down Biotech Stocks Worth Buying? Motley Fool
Jul-22-19 05:13PM  Here's Why Dynavax Technologies Fell Again Today Motley Fool -8.47%
Jul-19-19 09:56AM  Dynavax Technologies Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-14-19 07:03PM  3 Biotech Stocks That Could Double Your Money Motley Fool
Jul-11-19 11:55AM  Dynavax: Last Chance to Make Good GuruFocus.com
Jul-04-19 11:39AM  Why Dynavax Technologies' Stock Tanked in June Motley Fool
Jun-27-19 11:19AM  Heres What Hedge Funds Think About Dynavax Technologies Corporation (DVAX) Insider Monkey
Jun-03-19 04:05PM  Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference GlobeNewswire
02:15PM  Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavaxs SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting GlobeNewswire
Jun-01-19 02:15PM  Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting GlobeNewswire
May-27-19 05:00AM  Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business Zacks
May-26-19 05:03PM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-24-19 06:10PM  Here's Why Dynavax Technologies Is Tumbling Motley Fool -8.98%
05:41PM  East Bay biotech pivoted to cancer, found new space now CEO is leaving, 82 jobs are cut American City Business Journals
07:44AM  The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice Benzinga
May-23-19 05:25PM  Dynavax announces layoffs, CEO retirement MarketWatch
04:45PM  Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business GlobeNewswire
May-21-19 11:14AM  Could The Dynavax Technologies Corporation (NASDAQ:DVAX) Ownership Structure Tell Us Something Useful? Simply Wall St. +8.62%
May-20-19 12:29AM  Edited Transcript of DVAX earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-10-19 09:14AM  Hopeful Signs for These 2 Small Biotech Stocks TheStreet.com
May-09-19 02:08PM  Why Dynavax Technologies Stock Is Soaring Today Motley Fool +17.76%
01:33PM  Is Dynavax Technologies Corporation (DVAX) A Good Stock To Buy? Insider Monkey
May-08-19 09:23PM  Dynavax Technologies Corp (DVAX) Q1 2019 Earnings Call Transcript Motley Fool
07:45PM  Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:35PM  Dynavax Technologies: 1Q Earnings Snapshot Associated Press
04:05PM  Dynavax Announces First Quarter 2019 Financial Results GlobeNewswire
02:30PM  Dynavax Technologies Corp. to Host Earnings Call ACCESSWIRE
May-02-19 05:00PM  Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® in Adults With End-Stage Renal Disease GlobeNewswire
May-01-19 10:33AM  Analysts Estimate Dynavax Technologies (DVAX) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-25-19 04:05PM  Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8 GlobeNewswire
Apr-18-19 04:05PM  Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019 GlobeNewswire
Apr-06-19 10:42AM  Investors Who Bought Dynavax Technologies (NASDAQ:DVAX) Shares Three Years Ago Are Now Down 66% Simply Wall St.
Apr-03-19 10:02AM  After inking lease with cancer-fighting company, this new East Bay biotech project is full American City Business Journals -7.01%
Apr-02-19 01:00PM  Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting GlobeNewswire
07:30AM  The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial Benzinga
Mar-28-19 04:05PM  Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults GlobeNewswire
Mar-21-19 06:30AM  HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results CNW Group
Mar-20-19 04:20PM  Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019 GlobeNewswire -5.76%
Mar-18-19 04:05PM  Dynavax Exercises Option for $75 Million in Non-Dilutive Debt GlobeNewswire
Mar-07-19 09:44AM  Why Dynavax Technologies Cratered in February Motley Fool
Mar-06-19 04:05PM  Dynavax to Present at 39th Annual Cowen Healthcare Conference GlobeNewswire -6.04%
Mar-01-19 04:46PM  Edited Transcript of DVAX earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
09:00AM  Should You Be Concerned About Dynavax Technologies Corporations (NASDAQ:DVAX) Historical Volatility? Simply Wall St.
Feb-26-19 10:40PM  Dynavax Technologies Corporation (DVAX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-12-19 04:05PM  Dynavax Technologies to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26 GlobeNewswire
Feb-11-19 07:20AM  Recent Analysis Shows Corcept Therapeutics, CDK Global, Dynavax Technologies, ICU Medical, American Vanguard, and Cabot Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-10-19 01:00PM  Why Dynavax Technologies Stock Marched Higher in January Motley Fool
Jan-29-19 04:05PM  Heather Rowe Named Dynavaxs Vice President of Investor Relations and Corporate Communications GlobeNewswire
Jan-16-19 08:00AM  Today's Research Reports on Trending Tickers: Dynavax Technologies and Tyme Technologies ACCESSWIRE
Jan-15-19 05:00PM  Why Dynavax Technologies Stock Fell 51% in 2018 Motley Fool +11.48%
12:18PM  Is Dynavax Technologies Corporation (NASDAQ:DVAX) Worth US$10.80 Based On Intrinsic Value? Simply Wall St.
Jan-09-19 10:07AM  2 Small-Caps That Should Continue to Stage Comebacks in 2019 TheStreet.com
Jan-08-19 09:00AM  Sams Club and Dynavax Technologies Corporation Announce Collaboration to Make HEPLISAV-B® Available to Sams Club Patients GlobeNewswire
Jan-07-19 08:17AM  Here's Why Dynavax Technologies Slid 19% in December Motley Fool
Jan-03-19 04:05PM  Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-30-18 03:27PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-27-18 12:57PM  Edited Transcript of DVAX earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-17-18 01:38AM  Is Dynavax Technologies Corporation (DVAX) Going to Burn These Hedge Funds? Insider Monkey
Nov-12-18 03:37PM  Why Dynavax Technologies Corporation Fell 20.2% in October Motley Fool
Nov-08-18 08:55AM  Consolidated Research: 2018 Summary Expectations for MYR Group, L.B. Foster, The Habit Restaurants, Viper Energy Partners LP, Twin Disc, and Dynavax Technologies Fundamental Analysis, Key Performance Indications GlobeNewswire +5.97%
Nov-05-18 05:39PM  Dynavax Technologies: 3Q Earnings Snapshot Associated Press
04:01PM  Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations GlobeNewswire
03:00PM  Don't Waste Your Money on Penny Stocks; These 3 Stocks Are Better Buys Motley Fool
Oct-29-18 06:00AM  Dynavax to Host Third Quarter 2018 Financial Results Conference Call GlobeNewswire -7.93%
Oct-26-18 10:30AM  Dynavax Technologies (DVAX) Q3 Earnings Preview: What to Watch Ahead of the Release Zacks
Oct-24-18 08:41AM  Dynavax (DVAX) Catches Eye: Stock Jumps 9.8% Zacks -6.33%
Oct-22-18 04:29PM  Why American Railcar Industries, PetMed Express, and Dynavax Technologies Jumped Today Motley Fool +11.02%
10:23AM  Why Dynavax Technologies Corporation Is Surging Today Motley Fool
Oct-20-18 08:45AM  Dynavaxs SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress GlobeNewswire
Oct-18-18 11:05AM  Medical Companies You Need to Have on Your Radar ACCESSWIRE
Oct-17-18 07:20AM  Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis Discovering Underlying Factors of Influence GlobeNewswire
Oct-15-18 06:00AM  Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer GlobeNewswire
Oct-14-18 01:21PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Oct-10-18 10:30AM  Major Biotech Announcements Moving the Market ACCESSWIRE
Oct-09-18 10:45AM  ARWR Stock Sinks After Signing a Big Collaboration Deal InvestorPlace
06:00AM  Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress GlobeNewswire
Oct-03-18 11:26AM  Why Dynavax Technologies Corporation Stock Struggled in September Motley Fool
Oct-01-18 09:52AM  Health Care Digest: An East Bay biotech coup, a Nobel effort and an A's bobblehead American City Business Journals -5.32%
Sep-29-18 06:31PM  3 Top Stocks That Aren't on Wall Street's Radar Motley Fool
Sep-27-18 04:01PM  Dynavax to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-04-18 06:30AM  Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer GlobeNewswire
Aug-28-18 06:30AM  Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101 GlobeNewswire
Aug-19-18 09:01AM  Is Dynavax Technologies Corporation a Buy? Motley Fool
Aug-18-18 01:46AM  Edited Transcript of DVAX earnings conference call or presentation 6-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-18 08:44AM  Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation Motley Fool
Aug-14-18 07:45AM  Consolidated Research: 2018 Summary Expectations for National Instruments, Dynavax Technologies, BWX Technologies, Fossil Group, GCP Applied Technologies, and Stratasys Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-06-18 06:25PM  Dynavax Technologies (DVAX) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:20PM  Dynavax Technologies: 2Q Earnings Snapshot Associated Press
04:01PM  Dynavax Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  Dynavax Technologies Corporation to Host Earnings Call ACCESSWIRE
Jul-30-18 02:45PM  Dynavax to Host Second Quarter 2018 Financial Results Conference Call GlobeNewswire
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its product candidates include SD-101, a cancer immunotherapy that is in Phase 2 clinical trials; DV281, an investigational TLR9 agonist, which is in Phase I clinical trial for the treatment of non-small cell lung cancer; and AZD1419, which is in Phase IIa clinical trial to treat asthma. Dynavax Technologies Corporation has a collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Phillips Peggy VDirectorAug 12Buy3.0016,66649,99830,468Aug 12 07:27 PM
CANO FRANCISDirectorAug 12Buy3.0016,66750,00116,667Aug 12 07:24 PM
Novack David FCo-President and Senior VPAug 12Buy3.0016,66750,001118,484Aug 12 07:23 PM
COFFMAN ROBERTSenior Vice PresidentJun 04Sale4.5832,218147,68777,768Jun 04 07:07 PM
OSTRACH MICHAEL SSenior Vice PresidentFeb 28Option Exercise5.403,75020,250122,216Mar 01 07:55 PM
Johnson David LouisVice PresidentFeb 28Sale9.0320,765187,50832,021Mar 01 08:01 PM
COFFMAN ROBERTSenior Vice PresidentFeb 28Sale9.0363,202570,71477,768Mar 01 07:57 PM
OSTRACH MICHAEL SSenior Vice PresidentFeb 28Sale8.9435,444316,76486,772Mar 01 07:55 PM
Johnson David LouisVice PresidentFeb 05Option Exercise0.004,687041,833Feb 07 06:11 PM
Johnson David LouisVice PresidentDec 31Option Exercise0.0015,000037,146Jan 03 08:34 PM
CANO FRANCISDirectorDec 06Sale10.472,00020,9420Dec 07 07:23 PM